Zoliflodacin and gepotidacin make oral therapy viable again for urogenital gonorrhea, yet lower pharyngeal efficacy and weak resistance surveillance mean clinicians must adopt cautious, targeted use.
After years of creating highly specialized software, researchers used supercomputer clusters to finally solve the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results